Dec 2023 $3 M No. 4 $2 to $10 million 1
Biolase Technology Inc.: Raise no. 4, Dec 2023 × Investors in this round 1 investor had bought by the notice of Dec 20, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Warrants and Shares of Common Stock Underlying the Common Warrants Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $96,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Jennifer R. Bright · Executive Officer John R. Beaver · Executive Officer, Director Carol Gomez Summerhays · Director Jess T. Roper · Director Jonathan R. Lord · Director Kathleen T. O'Loughlin · Director Kenneth P. Yale · Director Martha T. Somerman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in no state named, and outside the US Remarks in the notice On the amounts: “The Issuer issued securities in a registered direct offering for gross proceeds of approximately $1.36 million and in a concurrent private placement issued warrants to purchase an aggregate of 2,221,880 shares of common stock”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by John R. Beaver, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2023. Read the notice at the SEC .
equity, options SEC Jun 2020 $7 M No. 3 $2 to $10 million 9
Biolase Technology Inc.: Raise no. 3, Jun 2020 × Investors in this round 9 investors had bought by the notice of Jun 12, 2020: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $483,840
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John R. Beaver · Executive Officer Todd A. Norbe · Executive Officer, Director Elaine C. Wagner · Director Garrett T. Sato · Director Jess T. Roper · Director Jonathan T. Lord · Director Michael C. DiTolla · Director Richard B. Lanman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer The Benchmark Company LLC (CRD 22982) · New York, New York Sold in CA, IL, KY, NY Colliers Securities LLC (CRD 7477) · Minneapolis, Minnesota Sold in CA, IL, KY, NY Remarks in the notice On the amounts: “Combined purchase price of 10,800,000 shares of common stock (CS) in a registered direct offering & warrants in private placement to purchase 10,800,000 shares of CS with an exercise price of $0.515 per share.”Signed by John R. Beaver, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 12, 2020. Read the notice at the SEC .
equity, options SEC Oct 2019 $4 M No. 2 $2 to $10 million 4
Biolase Technology Inc.: Raise no. 2, Oct 2019 × Investors in this round 4 investors had bought by the notice of Nov 5, 2019: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John R. Beaver · Executive Officer Todd A. Norbe · Executive Officer, Director Elaine C. Wagner, D.D.S. · Director Garrett T. Sato · Director Jess T. Roper · Director Jonathan T. Lord, M.D. · Director Richard B. Lanman, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Todd A. Norbe, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 5, 2019. Read the notice at the SEC .
equity SEC Jun 2011 $9 M No. 1 $2 to $10 million 7
Biolase Technology Inc.: Raise no. 1, Jun 2011 × Investors in this round 7 investors had bought by the notice of Jul 11, 2011: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions $451,200
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Federico Pignatelli · Executive Officer, Director Frederick D Furry · Executive Officer Alexander K Arrow · Director Gregory E Lichtwardt · Director Norman J Nemoy · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Rodman & Renshaw, LLC · New York, New York Sold in IL, NY, TX Signed by Federico Pignatelli, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2011. Read the notice at the SEC .
equity, options SEC